# Understanding the Scientific EXPERT Act of 2024

This bill creates a new process for discussing how to develop drugs for rare diseases. Right now, when pharmaceutical companies are developing treatments for uncommon conditions, they often work separately with the FDA (Food and Drug Administration) to figure out the best approach. This bill establishes organized meetings where doctors, drug companies, patient groups, and FDA officials can all sit down together to talk through the scientific challenges and find common ground on how to move forward.

The meetings would be run by the Reagan-Udall Foundation, an independent organization that works with the FDA. The foundation would hold at least four of these meetings every year, each focused on a different rare disease or group of rare diseases. Before each meeting, a steering committee made up of medical experts, patients, industry representatives, and FDA staff would decide which diseases to discuss based on factors like how many people are affected, whether there are multiple treatments being developed, and whether clearer guidance would help speed things up. During the meetings, participants would discuss practical questions like what kind of clinical trials make sense, what measurements should be used to determine if a drug works, and how to handle situations where traditional testing methods don't fit the disease.

After each meeting, the foundation would publish a summary of what was discussed, highlighting where everyone agreed and where more work is needed. When the FDA later approves a drug that was discussed at one of these meetings, the agency would have to publicly explain how the meeting's input influenced their decision. This transparency helps ensure the meetings actually matter and aren't just talk. The bill also requires the FDA to submit yearly reports to Congress about how many meetings happened, who participated, and whether the discussions actually helped speed up drug development. The whole program would cost about $1 million per year through 2029.